Total de visites
| Visites | |
|---|---|
| Safety ... | 66 |
Total de visites per mes
| de novembre 2023 | de desembre 2023 | de gener 2024 | de febrer 2024 | de març 2024 | d’abril 2024 | de maig 2024 | |
|---|---|---|---|---|---|---|---|
| Safety ... | 2 | 2 | 1 | 0 | 2 | 3 | 0 |
Total de descàrregues del fitxer
| Visites | |
|---|---|
| safety_immunogenicity_protein_based_phh_1v_compared_bnt62b2_as_a_heterologous_sars_cov_2_booster_vaccine_adults_vaccinated_against_covid_19_2023.pdf | 45 |
| safety_immunogenicity_protein_based_phh_1v_compared_bnt62b2_as_a_heterologous_sars_cov_2_booster_vaccine_adults_vaccinated_against_covid_19_2023_material_suplementari1.pdf | 19 |
| safety_immunogenicity_protein_based_phh_1v_compared_bnt62b2_as_a_heterologous_sars_cov_2_booster_vaccine_adults_vaccinated_against_covid_19_2023_material_suplementari2.pdf | 15 |
| safety_immunogenicity_protein_based_phh_1v_compared_bnt62b2_as_a_heterologous_sars_cov_2_booster_vaccine_adults_vaccinated_against_covid_19_2023_material_suplementari3.pdf | 7 |
| safety_immunogenicity_protein_based_phh_1v_compared_bnt62b2_as_a_heterologous_sars_cov_2_booster_vaccine_adults_vaccinated_against_covid_19_2023_material_suplementari4.pdf | 7 |
| safety_immunogenicity_protein_based_phh_1v_compared_bnt62b2_as_a_heterologous_sars_cov_2_booster_vaccine_adults_vaccinated_against_covid_19_2023_material_suplementari5.pdf | 5 |
| safety_immunogenicity_protein_based_phh_1v_compared_bnt62b2_as_a_heterologous_sars_cov_2_booster_vaccine_adults_vaccinated_against_covid_19_2023_material_suplementari6.pdf | 3 |
Visites per país
| Visites | |
|---|---|
| Estats Units | 31 |
| Espanya | 12 |
| França | 10 |
| Irlanda | 4 |
| Canadà | 2 |
| Alemanya | 2 |
| Xina | 1 |
| Regne Unit | 1 |
| Índia | 1 |
| Tailàndia | 1 |
Visites per ciutat
| Visites | |
|---|---|
| Boydton | 7 |
| Paris | 5 |
| Ashburn | 4 |
| Barcelona | 4 |
| Dublin | 4 |
| Vic | 3 |
| Chicago | 2 |
| Fort Worth | 2 |
| Girona | 2 |
| Santa Coloma de Gramenet | 2 |